Skip to content

Mike Clark

  • PhD
  • Retired (2014) as Reader in Therapeutic and Molecular Immunology
  • University of Cambridge
  • 31h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 5055CitationsNumber of citations received by Mike's publications. Updated daily.

Research interests

Antibody engineering of Fc regions to study interactions with Fc Receptors and complement. Therapeutic applications of engineered antibodies and their derivatives.

About

Extensive experience of the development of antibody based therapeutics including recombinant antibodies. An inventor of the first fully humanised antibody CAMPATH (alemtuzumab) and several other humanised therapeutic antibodies to antigens such as CD3 (TRX4 otelixizumab). Alemtuzumab is approved for treatment of B-CLL (FDA and EMA 2001) and MS (EMA 2013) under the trade name Lemtrada. More recent work has concentrated on antibodies with modified Fc properties for use in treatment of FMAITP.

Co-authors (285)

  • Jafar Nikzad

Publications (5)

  • Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport

    • Stapleton N
    • Armstrong-Fisher S
    • Andersen J
    • et al.
    N/AReaders
    0Citations
    Get full text
  • When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions

    • Bradbury A
    • Trinklein N
    • Thie H
    • et al.
    N/AReaders
    2Citations
    Get full text
  • Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies

    • de Gast G
    • Van Houten A
    • Haagen I
    • et al.
    N/AReaders
    58Citations
    Get full text
  • Monoclonal-Antibody Therapy in Systemic Vasculitis

    • Mathieson P
    • Cobbold S
    • Hale G
    • et al.
    N/AReaders
    193Citations
    Get full text
  • REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

    • Hale G
    • Clark M
    • Marcus R
    • et al.
    N/AReaders
    443Citations
    Get full text

Professional experience

Retired (2014) as Reader in Therapeutic and Molecular Immunology

University of Cambridge

October 2014 - Present

Reader in Therapeutic and Molecular Immunology

University of Cambridge

October 2007 - September 2014(7 years)

Lecturer in Immunology

University of Cambridge

July 1990 - September 2007(17 years)

Postdoctoral Research Scientist

University of Cambridge

October 1981 - June 1990(9 years)

Research Student

MRC Laboratory of Molecular Biology

October 1978 - September 1981(3 years)

Education

PhD "Antibodies in Somatic Cell Hybrids"

Darwin College, University of Cambridge

October 1978 - September 1981(3 years)

B.Sc (Hons) in Biochemistry

UCL - University College London

October 1975 - July 1978(3 years)